Nxera Pharma Co., Ltd.

POWER SEARCH PRICING

SOLUTIONS

nxera pharma co., ltd. Company Information

Live

MatureLargeHealthy

Company Number

FC024112

Website

https://soseiheptares.com

Registered Address

midtown east 7f 9-7-2 akasaka, minato-ku, tokyo 107-0052

Industry

Telephone

Next Accounts Due

December 2025

Group Structure

View All

Directors

Shinichi Tamura22 Years

Tomohiro Tohyama13 Years

View All

Shareholders

-0%

nxera pharma co., ltd. Estimated Valuation

£0

Pomanda estimates the enterprise value of NXERA PHARMA CO., LTD. at £0 based on a Turnover of £66.3m and 0x industry multiple (adjusted for size and gross margin).

Edit your figures and get a professional valuation report.

Nxera Pharma Co., Ltd. is a live company located in tokyo 107-0052. Founded in April 2002, it's largest shareholder is unknown. Nxera Pharma Co., Ltd. is a mature, large sized company, Pomanda has estimated its turnover at £66.3m with healthy growth in recent years.

View Sample

Upgrade for unlimited company reports & a free credit check

There is insufficient data available to calculate a health check for Nxera Pharma Co., Ltd.. Company Health Check FAQs

Health Rating0out of 5

0 Strong

0 Regular

0 Weak

Size

There is insufficient data available for this Key Performance Indicator!

Growth

There is insufficient data available for this Key Performance Indicator!

EXPORT

Nxera Pharma Co., Ltd.'s latest turnover from December 2023 is £66.3 million and the company has net assets of £346.9 million. According to their latest financial statements, we estimate that Nxera Pharma Co., Ltd. has no employees and maintains cash reserves of £254.8 million as reported in the balance sheet.

Data source: Companies House, Pomanda Estimates

	Dec 2023	Dec 2022	Dec 2020	Dec 2019	Dec 2018	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013	Mar 2012	Mar 2011	Mar 2010
Turnover	66,287,063	80,841,554	58,486,572	64,333,907	20,526,015	49,582,947	134,747,273	60,121,837	27,077,323	11,141,125	10,544,516	4,891,719	4,064,500	5,216,574
Other Income Or Grants	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cost Of Sales	16,107,040	4,808,227	5,033,735	5,629,051	2,394,225	0	0	29,504	501,569	1,353,199	1,753,381	1,440,275	287,260	724,355
Gross Profit	50,180,023	76,033,327	53,452,838	58,704,855	18,131,790	49,582,947	134,747,273	60,092,333	26,575,755	9,787,925	8,791,135	3,451,444	3,777,240	4,492,219
Admin Expenses	99,643,485	58,192,003	47,314,460	56,164,836	59,112,350	62,568,849	45,613,471	64,107,610	17,295,647	5,716,555	4,196,306	14,583,744	14,419,173	15,012,240
Operating Profit	-49,463,462	17,841,324	6,138,378	2,540,019	-40,980,560	-12,985,902	89,133,802	-4,015,277	9,280,108	4,071,370	4,594,829	-11,132,300	-10,641,933	-10,520,021
Interest Payable	12,955,211	3,925,507	3,823,257	3,261,013	9,927,101	8,832,965	3,414,843	32,284,785	1,084,273	261,579	0	0	0	0
Interest Receivable	6,963,101	3,442,607	10,768,620	5,450,456	3,101,772	741,427	10,843,373	29,504	2,987,283	161,758	552,390	1,911	5,847	23,102
Pre-Tax Profit	-55,455,572	5,597,482	10,728,932	3,532,213	-51,765,294	-26,391,958	88,992,657	-24,318,697	9,596,186	3,971,550	5,147,220	-11,067,922	-10,616,346	-10,022,706
Tax	18,106,140	-3,613,959	-945,892	5,939,939	9,040,881	7,471,305	-23,747,059	12,908,013	-5,834,422	4,243,264	-41,764	-17,640	-1,219	-12,252
Profit After Tax	-37,349,431	1,983,523	9,783,040	9,472,152	-42,724,414	-18,920,653	65,245,598	-11,410,684	3,761,764	8,214,814	5,105,456	-11,085,562	-10,617,565	-10,034,957
Dividends Paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Retained Profit	-37,349,431	1,983,523	9,783,040	9,472,152	-42,717,267	-18,920,653	66,371,997	-12,251,548	3,724,884	8,214,814	5,105,456	-11,085,562	-10,617,565	-10,034,957
Employee Costs	0	25,328,865	0	0	0	0	0	0	0	0	0	0	0	0
Number Of Employees	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EBITDA*	-36,596,524	24,825,195	6,138,378	2,540,019	-40,980,560	-12,985,902	89,133,802	-4,015,277	9,280,108	4,071,370	4,594,829	-11,132,300	29,143,013	-1,512,112

* Earnings Before Interest, Tax, Depreciation and Amortisation

	Dec 2023	Dec 2022	Dec 2020	Dec 2019	Dec 2018	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013	Mar 2012	Mar 2011	Mar 2010
Tangible Assets	75,799,666	20,993,153	56,297,129	64,512,502	58,311,893	51,436,515	8,120,054	14,582,367	4,964,053	5,219,078	618,026	2,011,930	590,078	526,998
Intangible Assets	422,937,006	132,054,878	171,557,084	181,002,778	204,002,287	223,533,186	221,886,362	256,235,124	281,320,925	33,093,861	31,681,969	30,777,032	39,784,947	48,792,856
Investments & Other	16,958,604	9,019,319	30,956,475	36,989,019	36,871,068	43,081,200	4,313,110	12,229,420	2,684,866	0	0	214,542	0	0
Debtors (Due After 1 year)	20,801,031	332,318	46,302	271,199	0	0	0	0	0	0	0	0	0	0
Total Fixed Assets	478,153,724	153,048,031	227,854,213	245,515,279	262,314,179	274,969,701	230,006,416	270,817,490	286,284,977	38,312,938	32,299,995	32,788,961	40,375,024	49,319,854
Stock & work in progress	15,073,738	166,159	0	0	0	0	0	0	0	0	0	0	357,253	0
Trade Debtors	21,502,015	7,181,185	6,211,139	12,726,551	7,054,031	5,368,218	9,852,427	715,473	18,299,875	537,007	234,531	187,237	284	233,516
Group Debtors	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Misc Debtors	4,792,649	5,602,674	0	0	0	0	0	3,459,347	7,110,471	0	0	0	0	0
Cash	254,768,504	345,595,176	264,638,179	101,699,960	134,076,615	201,618,307	99,087,474	74,261,643	41,106,489	38,835,197	13,658,534	8,028,904	9,934,588	10,538,518
misc current assets	31,056,159	4,325,327	4,306,125	3,300,701	18,131,790	13,416,982	3,835,460	0	0	805,610	181,028	913,900	335,484	447,373
total current assets	338,092,058	363,171,685	277,933,589	129,402,037	159,262,436	220,403,508	112,775,362	78,436,463	66,516,835	40,177,815	14,074,094	9,130,042	10,627,611	11,219,407
total assets	816,245,782	516,219,716	505,787,802	374,917,316	421,576,615	495,373,209	342,781,778	349,253,953	352,801,812	78,490,753	46,374,089	41,919,003	51,002,635	60,539,261
Bank overdraft	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Bank loan	30,105,936	0	0	0	0	0	0	0	0	0	0	0	0	0
Trade Creditors	581,557	0	9,974,864	8,010,319	14,865,638	17,188,280	11,028,730	9,846,970	10,016,618	840,048	1,430,537	538,774	634,894	498,269
Group/Directors Accounts	0	0	0	0	0	0	0	0	0	0	0	0	0	0
other short term finances	742,523	0	0	0	21,397,941	21,351,678	14,186,925	14,678,254	146,612,900	0	0	0	0	0
hp & lease commitments	4,320,134	913,874	1,124,487	1,157,560	0	0	0	0	0	0	0	0	0	0
other current liabilities	53,482,432	20,333,707	8,645,323	6,065,616	2,680,102	1,347,401	14,771,511	973,632	1,718,609	274,506	213,064	1,095,413	1,267,171	1,182,253
total current liabilities	89,232,584	21,247,584	19,744,675	15,233,496	38,943,682	39,887,360	39,987,168	25,498,858	158,348,128	1,114,556	1,643,602	1,634,188	1,902,066	1,680,524
loans	718,788,325	331,835,132	232,305,859	74,765,179	65,172,955	95,736,793	74,463,534	101,007,046	0	0	1,822,229	0	0	0
hp & lease commitments	20,691,989	8,188,524	11,006,746	11,271,332	0	0	0	0	0	0	0	0	0	0
Accruals and Deferred Income	0	0	0	0	0	0	0	154,896	213,904	71,669	90,223	0	0	0
other liabilities	0	0	7,157,031	5,920,095	30,495,997	33,342,838	38,532,829	74,261,642	51,912,340	37,140	37,080	0	0	0
provisions	20,499,868	31,570,212	32,504,298	26,564,360	36,335,048	43,872,530	45,269,836	54,405,430	65,720,226	0	0	0	0	0
total long term liabilities	380,104,327	194,141,233	139,562,111	61,509,458	85,463,121	106,972,268	100,627,361	152,122,778	84,986,357	108,809	1,949,533	0	0	0
total liabilities	469,336,911	215,388,817	159,306,786	76,742,954	124,406,803	146,859,628	140,614,529	177,621,636	243,334,485	1,223,365	3,593,135	1,634,188	1,902,066	1,680,524
net assets	346,908,871	300,830,899	346,481,016	298,154,518	297,148,371	348,485,064	202,138,733	170,702,941	107,689,709	77,267,388	42,780,954	38,583,174	49,100,569	58,858,738
total shareholders funds	346,908,871	300,830,899	346,481,016	298,154,518	297,148,370	348,485,065	202,138,732	170,702,941	107,689,709	77,267,388	42,780,954	38,583,174	49,100,569	58,858,738

	Dec 2023	Dec 2022	Dec 2020	Dec 2019	Dec 2018	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013	Mar 2012	Mar 2011	Mar 2010
Operating Activities
Operating Profit	-49,463,462	17,841,324	6,138,378	2,540,019	-40,980,560	-12,985,902	89,133,802	-4,015,277	9,280,108	4,071,370	4,594,829	-11,132,300	-10,641,933	-10,520,021
Depreciation	5,104,197	2,923,360	0	0	0	0	0	0	0	0	0	0	0	0
Amortisation	7,762,741	4,060,510	0	0	0	0	0	0	0	0	0	0	39,784,946	9,007,909
Tax	18,106,140	-3,613,959	-945,892	5,939,939	9,040,881	7,471,305	-23,747,059	12,908,013	-5,834,422	4,243,264	-41,764	-17,640	-1,219	-12,252
Stock	14,907,579	166,159	0	0	0	0	0	0	0	0	0	-357,253	357,253	0
Debtors	33,979,518	13,116,177	-6,740,309	5,943,720	-2,798,397	-4,484,209	5,677,607	-21,235,525	24,873,338	302,476	47,294	186,954	-233,233	233,516
Creditors	581,557	0	1,964,546	-6,855,319	3,836,907	6,159,549	1,181,760	-169,648	9,176,570	-590,489	891,763	-96,120	136,625	498,269
Accruals and Deferred Income	33,148,725	20,333,707	2,579,707	3,385,514	-12,091,409	-13,424,110	13,642,983	-803,985	1,586,338	42,888	-792,126	-171,758	84,918	1,182,253
Deferred Taxes & Provisions	-11,070,344	31,570,212	5,939,938	-9,770,688	-8,934,788	-1,397,306	-9,135,594	-11,314,796	65,720,226	0	0	0	0	0
Cash flow from operations	-44,717,543	59,832,818	22,416,986	-10,704,255	-46,330,572	-9,692,255	65,398,285	17,839,832	55,055,482	7,464,557	4,605,408	-11,247,519	29,239,317	-77,358
Investing Activities
capital expenditure	-358,555,579	-160,031,901	17,661,067	16,798,900	-32,307,764	-44,963,285	40,811,075	15,467,487	-247,972,039	-6,012,943	488,966	7,586,063	-30,840,117	-58,327,763
Change in Investments	7,939,285	9,019,319	-6,032,544	117,951	32,557,958	38,768,090	-7,916,310	9,544,554	2,684,866	0	-214,542	214,542	0	0
cash flow from investments	-366,494,864	-169,051,220	23,693,611	16,680,949	-64,865,722	-83,731,375	48,727,385	5,922,933	-250,656,905	-6,012,943	703,508	7,371,521	-30,840,117	-58,327,763
Financing Activities
Bank loans	30,105,936	0	0	0	0	0	0	0	0	0	0	0	0	0
Group/Directors Accounts	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Short Term Loans	742,523	0	0	-21,397,941	7,211,016	7,164,753	-491,329	-131,934,646	146,612,900	0	0	0	0	0
Long term loans	386,953,193	331,835,132	157,540,680	9,592,224	-9,290,579	21,273,259	-26,543,512	101,007,046	0	-1,822,229	1,822,229	0	0	0
Hire Purchase and Lease Commitments	15,909,725	9,102,398	-297,659	12,428,892	0	0	0	0	0	0	0	0	0	0
other long term liabilities	0	0	1,236,936	-24,575,902	-8,036,832	-5,189,991	-35,728,813	22,349,302	51,875,200	60	37,080	0	0	0
share issue	83,427,403	298,847,376	38,543,458	-8,466,005	137,726,905	165,266,985	-34,936,205	75,264,780	26,697,437	26,271,620	-907,676	568,167	859,397	68,893,695
interest	-5,992,110	-482,900	6,945,363	2,189,443	-6,825,329	-8,091,538	7,428,530	-32,255,281	1,903,010	-99,821	552,390	1,911	5,847	23,102
cash flow from financing	511,146,670	639,302,006	203,968,778	-30,229,289	120,785,181	180,423,468	-90,271,329	34,431,201	227,088,547	24,349,630	1,504,023	570,078	865,244	68,916,797
cash and cash equivalents
cash	-90,826,672	345,595,176	162,938,219	-32,376,655	34,989,141	102,530,833	24,825,831	33,155,154	2,271,292	25,176,663	5,629,630	-1,905,684	-603,930	10,538,518
overdraft	1	0	0	0	0	0	0	0	0	0	0	0	0	0
change in cash	-90,826,673	345,595,176	162,938,219	-32,376,655	34,989,141	102,530,833	24,825,831	33,155,154	2,271,292	25,176,663	5,629,630	-1,905,684	-603,930	10,538,518

Very Low Risk70 - 100

Low Risk50 - 70

Moderate Risk30 - 50

High Risk20 - 30

Very High Risk0 - 20

Get a comprehensive credit check for nxera pharma co., ltd.. Get real-time insights into nxera pharma co., ltd.'s credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Perform a competitor analysis for nxera pharma co., ltd. by selecting its closest rivals, whether from the industry sector, other large companies, companies in Region Area area or any other competitors across 12 key performance metrics.

NXERA PHARMA CO., LTD. group structure

Nxera Pharma Co., Ltd. has no subsidiary companies.

Ultimate parent company

NXERA PHARMA CO., LTD.

FC024112

NXERA PHARMA CO., LTD. Shareholders

Nxera Pharma Co., Ltd. currently has 11 directors. The longest serving directors include Mr Shinichi Tamura (Sep 2002) and Tomohiro Tohyama (Jun 2011).

officer	country	age	start	end	role
Mr Shinichi Tamura		75 years	Sep 2002	-	Director
Tomohiro Tohyama	Japan	67 years	Jun 2011	-	Director
Ms Julia Gregory	England	72 years	Jun 2017	-	Director
Mr Kuniaki Kaga	Japan	73 years	Jun 2018	-	Director
Mr David Roblin	United Kingdom	58 years	Jun 2018	-	Director
Mr Noriaki Nagai	Japan	66 years	Mar 2019	-	Director
Mr Noriaki Nagai	Japan	66 years	Mar 2019	-	Director
Mr Rolf-Kristian Soderstrom	England	59 years	Mar 2020	-	Director
Miwa Seki		59 years	Mar 2022	-	Director
Mr Christopher Cargill	United Kingdom	40 years	Mar 2022	-	Director

P&L

December 2023

turnover

66.3m

-18%

operating profit

-49.5m

-377%

gross margin

75.8%

-19.51%

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

December 2023

net assets

346.9m

+0.15%

total assets

816.2m

+0.58%

cash

254.8m

-0.26%

net assets

Total assets minus all liabilities

Similar Companies

Similar companies unavailable for this selection

company number

FC024112

Type

Other

industry

incorporation date

April 2002

ultimate parent company

None

previous names

sosei group corporation (April 2024)

address

midtown east 7f 9-7-2 akasaka, minato-ku, tokyo 107-0052

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We did not find charges/mortgages relating to nxera pharma co., ltd..

nxera pharma co., ltd. Company Information

nxera pharma co., ltd. Estimated Valuation

nxera pharma co., ltd. Estimated Valuation

nxera pharma co., ltd. Estimated Valuation

Nxera Pharma Co., Ltd. Overview

Nxera Pharma Co., Ltd. Health Check

NXERA PHARMA CO., LTD. financials

nxera pharma co., ltd. Credit Report and Business Information

Nxera Pharma Co., Ltd. Competitor Analysis

nxera pharma co., ltd. Ownership

nxera pharma co., ltd. directors

nxera pharma co., ltd. company details

nxera pharma co., ltd. Charges & Mortgages

nxera pharma co., ltd. Companies House Filings - See Documents